BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15188622)

  • 1. [Small cell carcinoma of the prostate: a case report].
    Sakai H; Tsuruta T; Wajiki M
    Hinyokika Kiyo; 2004 Apr; 50(4):269-71. PubMed ID: 15188622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostate small cell carcinoma: report of two cases that differed in treatment responsiveness].
    Yoshida T; Nishimura K; Uemura M; Nakagawa K; Harada Y; Kanno N; Miyoshi S; Kawano K
    Hinyokika Kiyo; 2006 Nov; 52(11):891-4. PubMed ID: 17176877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report].
    Segawa N; Inamoto T; Ibuki N; Mizutani Y; Azuma H; Tsuji M; Katsuoka Y
    Hinyokika Kiyo; 2010 Jan; 56(1):49-54. PubMed ID: 20104011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Small cell carcinoma of the prostate: a case report].
    Yamamoto N; Kinoshita H; Inoue T; Kawakita S; Oguchi N; Muguruma K; Kawa G; Sakaguchi Y; Adachi Y; Sakaida N; Uemura Y; Matsuda T
    Hinyokika Kiyo; 2007 Sep; 53(9):665-9. PubMed ID: 17933147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
    Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
    Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Small cell carcinoma of the prostate: a case report].
    Tsukino H; Nagano M; Takehara T; Hamasuna R; Hasui Y; Osada Y
    Hinyokika Kiyo; 2001 Feb; 47(2):113-6. PubMed ID: 11280883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
    Mizusawa H; Kontani K; Okaneya T; Yoneyama T
    Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Small cell carcinoma of the prostate: a case report].
    Hashine K; Nakatsuji H; Karashima T; Sumiyoshi Y; Mandai K; Hata A
    Hinyokika Kiyo; 1998 Aug; 44(8):607-10. PubMed ID: 9783201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small cell carcinoma of the prostate with hypercalcemia.
    Hanazawa K; Higashi N; Kawachi Y; Suzuki F; Ishi K; Fujime M
    Int J Urol; 2005 Jan; 12(1):108-10. PubMed ID: 15661065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Small cell carcinoma of the prostate: an autopsy case report].
    Shimizu N; Miyatake R; Esa A; Ishikawa Y
    Hinyokika Kiyo; 2005 Jun; 51(6):399-402. PubMed ID: 16050480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
    Slovin SF
    Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Signet ring cell carcinoma of the prostate successfully treated with endocrine therapy: a case report].
    Ishizu K; Hirata H; Naito K; Sasaguri Y; Saito A
    Hinyokika Kiyo; 2003 May; 49(5):281-3. PubMed ID: 12822458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Marked effectiveness of the LH-RH analogue in a case of prostate cancer with large lymph node metastasis].
    Takezawa Y; Ohtake N; Nakano K; Uchida T; Okamura K; Yamanaka H
    Hinyokika Kiyo; 1994 Aug; 40(8):721-4. PubMed ID: 7942372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports].
    Kobayashi S; Tsukamoto T; Tohsaka A; Tohma T
    Hinyokika Kiyo; 2008 Jun; 54(6):423-6. PubMed ID: 18634439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.